VentiV Scientific has secured regulatory approval from China's National Medical Products Administration (NMPA) for its Control Medical Technology 7 – 11F Mechanical Thrombectomy platform, marking a significant entry into one of the world's largest medical markets.
The innovative medical device is designed to remove blood clots from peripheral vessels, addressing critical medical conditions such as peripheral arterial disease, acute limb ischemia, deep vein thrombosis, and pulmonary embolism. The platform's unique design offers clinicians enhanced treatment flexibility and potentially improved patient outcomes.
The thrombectomy system features catheters ranging from 7F to 11F outer diameter, with flexible dilators that enable improved tracking and access in peripheral vasculature. Its proprietary mechanical Aspirator and compatibility with various pumps allow for precise clot removal across different clot ages and sizes.
This regulatory clearance represents a strategic expansion for VentiV Scientific, facilitated by their partnership with Shanghai Easy-Flow MedTech. The device's introduction could significantly impact vascular disease treatment in China, where the peripheral thrombectomy market continues to grow.
By providing clinicians with advanced tools to manage complex vascular conditions, the platform potentially offers more effective and minimally invasive treatment options for patients suffering from various thrombotic disorders.
